Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Allergan Reports Third Quarter 2019 Financial Results

      - Q3 2019 GAAP Net Revenues of $4.05 Billion -

      - Q3 2019 GAAP Loss Per Share of $2.40; Non-GAAP Performance Net Income Per Share of $4.25 -

      - Q3 2019 GAAP Operating Loss of $596.6 Million; Non-GAAP Operating Income of $1.76 Billion -

      - Q3 2019 GAAP Net Revenue Driven by Growth in Top Promoted Products Including VRAYLAR®, BOTOX®, JUVÉDERM® Collection, OZURDEX® and Lo LOESTRIN® -

      - Continues to Advance R&D Pipeline on Key Programs Including BLA Filing for Abicipar for Wet Age-Related Macular Degeneration (AMD); Ubrogepant for Migraine and Bimatoprost SR for Glaucoma NDAs Under FDA Review -

      - Raises Guidance for Full-Year 2019 Net Revenue; Reaffirms Guidance for Full-Year 2019 Non-GAAP Performance Net Income Per Share -

      Allergan plc logo

      News provided by

      Allergan plc

      Nov 05, 2019, 07:00 ET

      Share this article

      Share this article


      DUBLIN, Nov. 5, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its third quarter 2019 financial results including GAAP net revenues of $4.05 billion, a 3.6 percent increase from the prior year quarter.

      THIRD QUARTER 2019 FINANCIAL RESULTS

      (unaudited; $ in millions, except per share
      amounts)


      Q3 '19



      Q3 '18



      Q3 '19 v

      Q3 '18



      Nine
      Months
      Ended
      September
      30, 2019



      Nine
      Months
      Ended
      September
      30, 2018



      2019 v
      2018


      Total Net Revenues


      $

      4,050.7



      $

      3,911.4




      3.6

      %


      $

      11,737.9



      $

      11,707.7




      0.3

      %


























      Operating (Loss) / Income


      $

      (596.6)



      $

      257.5




      (331.7)

      %


      $

      (4,168.7)



      $

      (863.5)




      (382.8)

      %

      Diluted EPS


      $

      (2.40)



      $

      (0.11)




      (2081.8)

      %


      $

      (15.04)



      $

      (2.50)




      (501.6)

      %

      SG&A Expense


      $

      1,994.1



      $

      1,044.8




      90.9

      %


      $

      4,303.9



      $

      3,328.2




      29.3

      %

      R&D Expense


      $

      474.5



      $

      424.2




      11.9

      %


      $

      1,359.5



      $

      1,588.1




      (14.4)

      %

      Tax Rate



      (2.4)

      %



      120.5

      %



      (122.9)

      %



      (5.3)

      %



      37.5

      %



      (42.8)

      %


























      Non-GAAP Net Revenues


      $

      4,025.7



      $

      3,911.4




      2.9

      %


      $

      11,712.9



      $

      11,682.7




      0.3

      %

      Non-GAAP Operating Income


      $

      1,759.3



      $

      1,905.1




      (7.7)

      %


      $

      5,235.2



      $

      5,638.0




      (7.1)

      %

      Non-GAAP Performance Net Income Per Share


      $

      4.25



      $

      4.25




      0.0

      %


      $

      12.43



      $

      12.41




      0.2

      %

      Non-GAAP Adjusted EBITDA


      $

      1,864.9



      $

      2,007.7




      (7.1)

      %


      $

      5,554.3



      $

      5,963.6




      (6.9)

      %

      Non-GAAP SG&A Expense


      $

      1,179.4



      $

      1,031.4




      14.3

      %


      $

      3,438.4



      $

      3,214.5




      7.0

      %

      Non-GAAP R&D Expense


      $

      448.9



      $

      393.7




      14.0

      %


      $

      1,293.8



      $

      1,138.4




      13.7

      %

      Non-GAAP Tax Rate



      11.2

      %



      14.2

      %



      (3.0)

      %



      12.3

      %



      14.2

      %



      (1.9)

      %


























       

      Executive Commentary

      "The third quarter 2019 results demonstrate our commitment to continued strong operational performance. The core business has grown and has been bolstered by significant pipeline progress, with three new molecular entities currently under regulatory review," said Brent Saunders, Chairman and CEO of Allergan. "VRAYLAR®, BOTOX® Cosmetic, JUVÉDERM®, BOTOX® Therapeutic, OZURDEX® and Lo LOESTRIN® continue to lead the way, with VRAYLAR® growing 70 percent and U.S. BOTOX® Cosmetic growing 10 percent in the third quarter from the prior year."

      Third Quarter 2019 Results

      GAAP operating loss in the third quarter of 2019 was $596.6 million compared to GAAP operating income of $257.5 million in the prior year quarter. Non-GAAP operating income in the third quarter of 2019 was $1.76 billion, a decrease of 7.7 percent versus the prior year quarter, partially impacted by divestitures, products that lost or are at risk of losing exclusivity and an increase in operating expenses. GAAP cash flow from operations for the third quarter of 2019 totaled $2.92 billion. Cash flow from operations in the third quarter includes a one-time tax refund of $1.6 billion of capital gains taxes previously paid and attributable to tax losses recorded in prior periods.

      Operating Expenses

      Total GAAP Selling, General and Administrative (SG&A) Expense was $1.99 billion for the third quarter of 2019, compared to $1.04 billion in the prior year quarter. Total non-GAAP SG&A expense was $1.18 billion for the third quarter of 2019, an increase of 14.3 percent from the prior year quarter, primarily related to an increase in spending to support key products and new product launches. GAAP R&D investment for the third quarter of 2019 was $474.5 million, compared to $424.2 million in the third quarter of 2018. Non-GAAP R&D investment for the third quarter of 2019 was $448.9 million, an increase of 14.0 percent compared to the prior year quarter, due to increased direct project spend to support pipeline advancement and new product launches.

      Amortization, Tax and Capitalization

      Amortization expense for the third quarter of 2019 was $1.54 billion, compared to $1.59 billion in the third quarter of 2018. The Company's GAAP tax rate was -2.4 percent in the third quarter of 2019. The Company's non-GAAP adjusted tax rate was 11.2 percent in the third quarter of 2019. As of September 30, 2019, Allergan had cash and marketable securities of $4.56 billion and outstanding indebtedness of $22.5 billion.

      Operating Charges and Impairments

      Allergan recorded a pre-tax charge of $750 million in the three months ended September 30, 2019 related to a settlement reached in principle by subsidiaries Forest Laboratories, LLC, Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. with direct purchasers of Namenda, resolving the class action litigation filed by that class of purchasers in the U.S. District Court for the Southern District of New York. The Company excludes operating charges, asset sales and impairments, net and in-process research and development impairments from its Non-GAAP performance net income attributable to shareholders as well as Adjusted EBITDA and Non-GAAP Operating Income.

      THIRD QUARTER 2019 BUSINESS SEGMENT RESULTS

      U.S. Specialized Therapeutics

      U.S. Specialized Therapeutics net revenues were $1.67 billion in the third quarter of 2019, a decrease of 2.1 percent versus the prior year quarter. Demand growth in BOTOX® and JUVÉDERM® Collection was offset by a decline in sales of CoolSculpting® compared to the prior year quarter and the divestiture of the Company's Medical Dermatology business on September 20, 2018. Segment gross margin for the third quarter of 2019 was 91.0 percent. Segment contribution for the third quarter of 2019 was $1.08 billion.

      Medical Aesthetics

      • Facial Aesthetics
        • BOTOX® Cosmetic net revenues in the third quarter of 2019 were $237.6 million, an increase of 10.0 percent from the prior year quarter.
        • JUVÉDERM® Collection (defined as JUVÉDERM®, VOLUMA® and other fillers) net revenues in the third quarter of 2019 were $134.8 million, an increase of 6.0 percent versus the prior year quarter.
      • Regenerative Medicine
        • ALLODERM® net revenues in the third quarter of 2019 were $95.0 million, a decrease of 10.2 percent versus the prior year quarter.
      • Body Contouring
        • CoolSculpting® net revenues (including both CoolSculpting® Systems/Applicators and Consumables) in the third quarter of 2019 were $53.0 million, a decrease of 37.6 percent from the prior year quarter.

      Neurosciences & Urology

      • BOTOX® Therapeutic net revenues in the third quarter of 2019 were $431.6 million, an increase of 5.9 percent versus the prior year quarter.

      Eye Care

      • RESTASIS® net revenues in the third quarter of 2019 were $286.8 million, a decrease of 3.8 percent versus the prior year quarter.
      • ALPHAGAN®/COMBIGAN® net revenues in the third quarter of 2019 were $90.9 million, a decrease of 4.7 percent versus the prior year quarter.
      • OZURDEX® net revenues in the third quarter of 2019 were $33.7 million, an increase of 17.8 percent versus the prior year quarter.

      U.S. General Medicine

      U.S. General Medicine net revenues in the third quarter of 2019 were $1.52 billion, an increase of 9.9 percent versus the prior year quarter. Demand growth in VRAYLAR®, VIIBRYD® and Lo LOESTRIN® was partially offset by lower revenues from products that lost exclusivity. Segment gross margin for the third quarter of 2019 was 83.9 percent. Segment contribution for the third quarter of 2019 was $967.2 million.

      Central Nervous System

      • VRAYLAR® net revenues were $234.6 million in the third quarter of 2019, an increase of 70.0 percent from the prior year quarter.
      • VIIBRYD®/FETZIMA® net revenues in the third quarter of 2019 were $105.1 million, an increase of 18.8 percent from the prior year quarter.

      Gastrointestinal, Women's Health & Diversified Brands

      • LINZESS® net revenues in the third quarter of 2019 were $214.7 million, an increase of 4.8 percent versus the prior year quarter.
      • Lo LOESTRIN® net revenues in the third quarter of 2019 were $161.4 million, an increase of 14.1 percent versus the prior year quarter.
      • BYSTOLIC®/BYVALSON® net revenues in the third quarter of 2019 were $152.2 million, an increase of 0.7 percent from the prior year quarter.

      International

      International net revenues in the third quarter of 2019 were $835.1 million, an increase of 5.0 percent versus the prior year quarter excluding foreign exchange impact. Growth in Facial Aesthetics and BOTOX® Therapeutic was partially offset by declines in textured breast implants. OZURDEX® growth was primarily related to a 2018 recall of OZURDEX® in certain international markets. Segment gross margin for the third quarter of 2019 was 82.7 percent. Segment contribution was $437.6 million.

      Facial Aesthetics

      • BOTOX® Cosmetic net revenues in the third quarter of 2019 were $165.6 million, an increase of 5.8 percent versus the prior year quarter excluding foreign exchange impact.
      • JUVÉDERM® Collection net revenues in the third quarter of 2019 were $144.7 million, an increase of 7.3 percent versus the prior year quarter excluding foreign exchange impact.

      Eye Care

      • LUMIGAN®/GANFORT® net revenues in the third quarter of 2019 were $89.7 million, a decrease of 1.4 percent versus the prior year quarter excluding foreign exchange impact.
      • OZURDEX® net revenues in the third quarter of 2019 were $63.8 million, an increase of 159.3 percent versus the prior year quarter excluding foreign exchange impact.

      Botox® Therapeutic

      • BOTOX® Therapeutic net revenues in the third quarter of 2019 were $93.9 million, an increase of 5.3 percent versus the prior year quarter excluding foreign exchange impact.

      PIPELINE UPDATE

      Allergan R&D continues to advance its pipeline. During the third quarter of 2019, the Company's key clinical developments included:

      • The U.S. Food and Drug Administration (FDA) approved Allergan's supplemental Biologics License Application (sBLA) to expand the BOTOX® (onabotulinumtoxinA) label for the treatment of pediatric patients ages two years and older with lower limb spasticity, excluding spasticity caused by cerebral palsy. This marks the 14th approved indication for BOTOX® and BOTOX® Cosmetic combined in the U.S., and the 11th BOTOX® therapeutic indication. The FDA approved BOTOX® (onabotulinumtoxinA) for pediatric upper limb spasticity in the second quarter of 2019.
      • The FDA accepted a Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin® therapy, in patients with neovascular (wet) age-related macular degeneration (nAMD). The FDA is expected to take action on the BLA mid-2020, with launch expected to follow. The European Medicines Agency (EMA) is also reviewing a Marketing Authorisation Application (MAA) for Abicipar in patients with nAMD. A decision from the European Commission is expected in the second half of 2020.
      • Allergan received FDA approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
      • Allergan dosed the first patient in a Phase 2b clinical trial of botulinum neurotoxin serotype E (BoNT/E) EB-001 for the treatment of glabellar frown lines.
      • Allergan completed enrollment of Part 1 of the Phase 3 AURORA NASH study in adults with stages 2/3 liver fibrosis.

      In addition to third quarter 2019 pipeline developments and the anticipated launch of abicipar listed above, Allergan expects three additional significant launches in the next twelve months:

      • Allergan anticipates a regulatory decision from the FDA in December 2019 for the Company's New Drug Application (NDA) for ubrogepant, an oral CGRP receptor antagonist for the acute treatment of migraine. Launch is expected to follow in the first half of 2020.
      • Allergan expects to launch CoolTone™, a body contouring device that uses magnetic muscle stimulation, or MMS technology, to strengthen, tone and firm the muscles of the abdomen, buttocks and thighs, in the fourth quarter of 2019, following FDA clearance in the second quarter of 2019.
      • FDA action is expected in the first half of 2020 on Allergan's NDA for Bimatoprost Sustained-Release, a biodegradable implant for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch is expected to follow in the first half of 2020.

      UPDATE ON PROPOSED ABBVIE TRANSACTION

      On October 14, 2019, Allergan shareholders voted to approve the proposed acquisition of Allergan by AbbVie. Additionally, both companies received a Request for Additional Information and Documentary Material (Second Request) from the U.S. Federal Trade Commission. Allergan and AbbVie continue to expect to close the transaction in early 2020, subject to customary closing conditions and regulatory approvals.

      FULL YEAR 2019 GUIDANCE  


      Previous Guidance


      Current Guidance


      Twelve Months Ending December 31, 2019


      Twelve Months Ending December 31, 2019


      GAAP

      NON-GAAP


      GAAP

      NON-GAAP







      Total Net Revenues

      ~$15.425 - $15.625
      billion

      ~$15.400 - $15.600
      billion


      ~$15.625 - $15.825
      billion

      ~$15.600 - $15.800
      billion

      Gross Margin (as a % of revenues)

      ~85.0% - 85.5%

      ~85.0% - 85.5%


      ~85.0%

      ~85.0%

      SG&A Expense

      ~$4.5 - $4.6 billion

      ~$4.4 - $4.5 billion


      ~$5.4 billion

      ~$4.5 billion

      R&D Expense

      ~$1.8 - $1.9 billion

      ~$1.6 - $1.7 billion


      ~$1.8 billion

      ~$1.75 billion

      Net Interest Expense/Other Income
      (Expense)

      ~ $775.0 million

      ~ $800.0 million


      ~ $725.0 million

      ~ $750.0 million

      Tax Rate

      ~ (5.0)%

      ~13.0%


      ~ (4.5)%

      ~12.0% - 12.5%

      Net Income / (Loss) Per Share1

      > ($12.03)

      > $16.55


      > ($14.98)

      > $16.55

      Average 2019 Share Count2

      ~ 329.0 million

      ~ 332.0 million


      ~ 329.0 million

      ~ 332.0 million

      Cash Flow from Operations

      $5.0 - $5.5 billion

      n.a.


      $6.0 - $6.5 billion

      n.a.







      (1) GAAP represents EPS for ordinary shareholders. GAAP income per share includes the impact of amortization of approximately $5.9 billion. Non-GAAP represents performance net income per share.

      (2) GAAP EPS shares do not include dilution of shares when earnings are a net loss. As such, the dilution impact of outstanding equity awards is not included in the forecasted shares.

      (3) The non-GAAP performance net income per share guidance for the twelve months ending December 31, 2019 of >$16.55 represents a "profit forecast" for the purposes of the Irish Takeover Rules. Please see page 7 of this press release for further information in relation to the basis of preparation of, assumptions behind and reports prepared in relation to that profit forecast.

       

      ADDITIONAL THIRD QUARTER DETAILS

      Due to the proposed acquisition of Allergan by AbbVie, Allergan is not hosting a conference call to discuss its third quarter results. For additional materials related to Allergan's third quarter results, please visit Allergan's Investor Relations website at https://www.allergan.com/investors/events-presentations.

      Allergan Contacts:


      Investors:


      Manisha Narasimhan, PhD

      (862) 261-7162



      Media:


      Lisa Brown 

      (862) 261-7320

       

      About Allergan plc

      Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

      With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

      For more information, visit Allergan's website at www.Allergan.com.

      Forward-Looking Statement

      Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected debt reduction, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; risks related to the proposed transaction between AbbVie and Allergan, such as, but not limited to, failure to complete the possible transaction, failure to realize the expected benefits of the possible transaction, and general economic and business conditions affecting the combined company following the consummation of the possible transaction; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

      Statements Required by the Irish Takeover Rules

      The non-GAAP performance net income per share guidance for the twelve months ending December 31, 2019 of >$16.55 represents a "profit forecast" for the purposes of the Irish Takeover Rules (the "Allergan Profit Forecast"). The basis of preparation of the Allergan Profit Forecast and the principal assumptions upon which the Allergan Profit Forecast is based are set out on pages 213 to 215 of the proxy statement sent to Allergan shareholders on or around September 16, 2019, a copy of which is available on Allergan's website, www.allergan.com. The reports on the Allergan Profit Forecast, as required by Rule 28.3 of the Irish Takeover Rules, have been prepared by (i) PricewaterhouseCoopers Ireland and (ii) J.P. Morgan Securities LLC. Copies of those reports have previously been mailed to Allergan shareholders with the above-mentioned proxy statement and are also available on Allergan's website, www.allergan.com.

      Except as described immediately above, no statement in this press release is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Allergan. No statement in this press release constitutes an asset valuation.

      The directors of Allergan accept responsibility for the information contained in this press release. To the best of the knowledge and belief of the directors of Allergan (who have taken all reasonable care to ensure that such is the case), the information contained in this press release is in accordance with the facts and does not omit anything likely to affect the import of such information.

      Any holder of 1% or more of any class of relevant securities of Allergan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

       

      The following presents Allergan plc's statement of operations for the three and nine months ended September 30, 2019 and 2018:

      Table 1




      ALLERGAN PLC

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited; in millions, except per share amounts)






















      Three Months Ended



      Nine Months Ended






      September 30,



      September 30,






      2019



      2018



      2019



      2018




      Net revenues


      $

      4,050.7



      $

      3,911.4



      $

      11,737.9



      $

      11,707.7























      Operating expenses:





















      Cost of sales (excludes amortization and impairment of acquired
      intangibles including product rights)



      639.0




      596.8




      1,789.1




      1,601.4




      Research and development



      474.5




      424.2




      1,359.5




      1,588.1




      Selling, general and administrative



      1,994.1




      1,044.8




      4,303.9




      3,328.2




      Amortization



      1,537.7




      1,588.5




      4,339.1




      4,983.2




      In-process research and development impairments



      -




      -




      436.0




      798.0




      Goodwill and other asset impairments / sales, net



      2.0




      (0.4)




      3,679.0




      272.3




      Total operating expenses



      4,647.3




      3,653.9




      15,906.6




      12,571.2




      Operating (loss) / income



      (596.6)




      257.5




      (4,168.7)




      (863.5)























      Non-operating income (expense):



















      Interest income



      20.5




      10.0




      51.5




      33.6




      Interest (expense)



      (193.9)




      (220.4)




      (591.1)




      (701.0)




      Other income (expense), net



      2.5




      130.0




      11.6




      266.6




      Total other income (expense), net



      (170.9)




      (80.4)




      (528.0)




      (400.8)




      (Loss) / income before income taxes and noncontrolling interest



      (767.5)




      177.1




      (4,696.7)




      (1,264.3)




      Provision / (benefit) for income taxes



      18.1




      213.4




      251.1




      (474.0)




      Net (loss)



      (785.6)




      (36.3)




      (4,947.8)




      (790.3)




      (Income) attributable to noncontrolling interest



      (1.2)




      (1.6)




      (6.0)




      (6.2)




      Net (loss) attributable to shareholders



      (786.8)




      (37.9)




      (4,953.8)




      (796.5)




      Dividends on preferred shares



      -




      -




      -




      46.4




      Net (loss) attributable to ordinary shareholders


      $

      (786.8)



      $

      (37.9)



      $

      (4,953.8)



      $

      (842.9)























      (Loss) per share attributable to ordinary shareholders:



















      Net (loss) per share - basic


      $

      (2.40)



      $

      (0.11)



      $

      (15.04)



      $

      (2.50)




      Net (loss) per share - diluted



      (2.40)




      (0.11)




      (15.04)




      (2.50)























      Weighted average shares outstanding:



















      Basic



      328.0




      339.0




      329.3




      337.6




      Diluted



      328.0




      339.0




      329.3




      337.6

























       

      The following table details Allergan plc's product revenue for significant promoted products globally, within the U.S., and international for the three and nine months ended September 30, 2019 and 2018.


      Table 2


      ALLERGAN PLC


      NET REVENUES TOP GLOBAL PRODUCTS


      (Unaudited; in millions)





















































      Three Months Ended September 30, 2019



      Three Months Ended September 30, 2018



      Movement




      US
      Specialized
      Therapeutics



      US
      General
      Medicine



      International



      Corporate



      Total



      US
      Specialized
      Therapeutics



      US
      General
      Medicine



      International



      Corporate



      Total



      Total
      Change



      Total
      Change
      Percentage



















































      Botox®


      $

      669.2



      $

      -



      $

      259.5



      $

      -



      $

      928.7



      $

      623.4



      $

      -



      $

      256.3



      $

      -



      $

      879.7



      $

      49.0




      5.6

      %

      Juvederm® Collection



      134.8




      -




      144.7




      -




      279.5




      127.2




      -




      138.6




      -




      265.8




      13.7




      5.2

      %

      Restasis®



      286.8




      -




      9.2




      -




      296.0




      298.0




      -




      13.6




      -




      311.6




      (15.6)




      (5.0)

      %

      Linzess®/Constella®



      -




      214.7




      6.7




      -




      221.4




      -




      204.8




      5.7




      -




      210.5




      10.9




      5.2

      %

      Vraylar®



      -




      234.6




      -




      -




      234.6




      -




      138.0




      -




      -




      138.0




      96.6




      70.0

      %

      Lumigan®/Ganfort®



      67.5




      -




      89.7




      -




      157.2




      78.0




      -




      94.8




      -




      172.8




      (15.6)




      (9.0)

      %

      Lo Loestrin®



      -




      161.4




      -




      -




      161.4




      -




      141.5




      -




      -




      141.5




      19.9




      14.1

      %

      Bystolic® /Byvalson®



      -




      152.2




      0.6




      -




      152.8




      -




      151.2




      0.5




      -




      151.7




      1.1




      0.7

      %

      Alphagan®/Combigan®



      90.9




      -




      40.4




      -




      131.3




      95.4




      -




      40.5




      -




      135.9




      (4.6)




      (3.4)

      %

      Eye Drops



      62.0




      -




      63.8




      -




      125.8




      54.8




      -




      66.8




      -




      121.6




      4.2




      3.5

      %

      Viibryd®/Fetzima®



      -




      105.1




      3.0




      -




      108.1




      -




      88.5




      1.8




      -




      90.3




      17.8




      19.7

      %

      Ozurdex ®



      33.7




      -




      63.8




      -




      97.5




      28.6




      -




      25.8




      -




      54.4




      43.1




      79.2

      %

      Alloderm®



      95.0




      -




      2.1




      -




      97.1




      105.8




      -




      1.0




      -




      106.8




      (9.7)




      (9.1)

      %

      Coolsculpting® Consumables



      40.4




      -




      21.6




      -




      62.0




      55.5




      -




      14.2




      -




      69.7




      (7.7)




      (11.0)

      %

      Zenpep®



      -




      74.2




      0.7




      -




      74.9




      -




      62.1




      -




      -




      62.1




      12.8




      20.6

      %

      Breast Implants



      58.5




      -




      5.7




      -




      64.2




      58.2




      -




      35.6




      -




      93.8




      (29.6)




      (31.6)

      %

      Carafate ® /Sulcrate ®



      -




      55.1




      0.8




      -




      55.9




      -




      53.4




      0.7




      -




      54.1




      1.8




      3.3

      %

      Armour Thyroid



      -




      54.4




      -




      -




      54.4




      -




      48.0




      -




      -




      48.0




      6.4




      13.3

      %

      Viberzi®



      -




      50.1




      0.6




      -




      50.7




      -




      46.8




      0.3




      -




      47.1




      3.6




      7.6

      %

      Skin Care



      36.1




      -




      4.0




      -




      40.1




      32.2




      -




      3.7




      -




      35.9




      4.2




      11.7

      %

      Teflaro®



      -




      38.4




      2.1




      -




      40.5




      -




      33.4




      -




      -




      33.4




      7.1




      21.3

      %

      Saphris®



      -




      34.5




      -




      -




      34.5




      -




      36.4




      -




      -




      36.4




      (1.9)




      (5.2)

      %

      Asacol®/Delzicol®



      -




      11.9




      7.2




      -




      19.1




      -




      32.1




      10.9




      -




      43.0




      (23.9)




      (55.6)

      %

      Avycaz®



      -




      29.6




      -




      -




      29.6




      -




      24.7




      -




      -




      24.7




      4.9




      19.8

      %

      Coolsculpting® Systems & Add On
      Applicators



      12.6




      -




      11.4




      -




      24.0




      29.4




      -




      8.3




      -




      37.7




      (13.7)




      (36.3)

      %

      Namzaric®



      -




      22.4




      -




      -




      22.4




      -




      28.0




      -




      -




      28.0




      (5.6)




      (20.0)

      %

      Savella®



      -




      24.0




      -




      -




      24.0




      -




      22.4




      -




      -




      22.4




      1.6




      7.1

      %

      Dalvance®



      -




      23.2




      1.4




      -




      24.6




      -




      9.2




      -




      -




      9.2




      15.4




      167.4

      %

      Liletta®



      -




      19.9




      -




      -




      19.9




      -




      12.7




      -




      -




      12.7




      7.2




      56.7

      %

      Canasa®/Salofalk®



      -




      5.8




      4.4




      -




      10.2




      -




      46.8




      4.4




      -




      51.2




      (41.0)




      (80.1)

      %

      Rapaflo®



      5.2




      -




      1.5




      -




      6.7




      20.5




      -




      1.8




      -




      22.3




      (15.6)




      (70.0)

      %

      Kybella® /Belkyra®



      5.3




      -




      0.3




      -




      5.6




      5.2




      -




      1.6




      -




      6.8




      (1.2)




      (17.6)

      %

      Namenda®



      -




      4.0




      -




      -




      4.0




      -




      16.3




      -




      -




      16.3




      (12.3)




      (75.5)

      %

      Aczone®



      3.4




      -




      -




      -




      3.4




      17.4




      -




      0.1




      -




      17.5




      (14.1)




      (80.6)

      %

      Other Products Revenues



      69.4




      203.1




      89.9




      26.2




      388.6




      76.6




      185.0




      94.6




      2.3




      358.5




      30.1




      8.4

      %

      Total Net Revenues


      $

      1,670.8



      $

      1,518.6



      $

      835.1



      $

      26.2




      4,050.7



      $

      1,706.2



      $

      1,381.3



      $

      821.6



      $

      2.3




      3,911.4



      $

      139.3




      3.6

      %





































































































      1Botox® is comprised of the following:

















































      Botox® Therapeutics



      431.6




      -




      93.9




      -




      525.5




      407.4




      -




      92.9




      -




      500.3




      25.2




      5.0

      %

      Botox®  Cosmetics



      237.6




      -




      165.6




      -




      403.2




      216.0




      -




      163.4




      -




      379.4




      23.8




      6.3

      %















































































































































































































































































































































































































































































































































































































      Nine Months Ended September 30, 2019



      Nine Months Ended September 30, 2018



      Movement




      US
      Specialized
      Therapeutics



      US
      General
      Medicine



      International



      Corporate



      Total



      US
      Specialized
      Therapeutics



      US
      General
      Medicine



      International



      Corporate



      Total



      Total
      Change



      Total
      Change
      Percentage



















































      Botox®


      $

      1,995.7



      $

      -



      $

      775.4



      $

      -



      $

      2,771.1



      $

      1,854.4



      $

      -



      $

      777.1



      $

      -



      $

      2,631.5



      $

      139.6




      5.3

      %

      Juvederm® Collection



      421.1




      -




      475.2




      -




      896.3




      389.8




      -




      440.8




      -




      830.6




      65.7




      7.9

      %

      Restasis®



      829.4




      -




      31.5




      -




      860.9




      872.0




      -




      47.9




      -




      919.9




      (59.0)




      (6.4)

      %

      Linzess®/Constella®



      -




      572.0




      17.0




      -




      589.0




      -




      555.9




      17.7




      -




      573.6




      15.4




      2.7

      %

      Vraylar®



      -




      574.4




      -




      -




      574.4




      -




      336.6




      -




      -




      336.6




      237.8




      70.6

      %

      Lumigan®/Ganfort®



      187.3




      -




      265.2




      -




      452.5




      217.8




      -




      295.7




      -




      513.5




      (61.0)




      (11.9)

      %

      Lo Loestrin®



      -




      432.7




      -




      -




      432.7




      -




      383.9




      -




      -




      383.9




      48.8




      12.7

      %

      Bystolic® /Byvalson®



      -




      431.0




      1.5




      -




      432.5




      -




      432.1




      1.6




      -




      433.7




      (1.2)




      (0.3)

      %

      Alphagan®/Combigan®



      265.5




      -




      118.9




      -




      384.4




      277.7




      -




      129.3




      -




      407.0




      (22.6)




      (5.6)

      %

      Eye Drops



      169.2




      -




      176.5




      -




      345.7




      154.8




      -




      208.0




      -




      362.8




      (17.1)




      (4.7)

      %

      Viibryd®/Fetzima®



      -




      297.9




      7.8




      -




      305.7




      -




      246.9




      4.9




      -




      251.8




      53.9




      21.4

      %

      Ozurdex ®



      93.9




      -




      207.9




      -




      301.8




      81.7




      -




      158.1




      -




      239.8




      62.0




      25.9

      %

      Alloderm®



      291.2




      -




      5.9




      -




      297.1




      312.4




      -




      5.5




      -




      317.9




      (20.8)




      (6.5)

      %

      Coolsculpting® Consumables



      148.9




      -




      59.7




      -




      208.6




      180.8




      -




      40.8




      -




      221.6




      (13.0)




      (5.9)

      %

      Zenpep®



      -




      207.2




      0.7




      -




      207.9




      -




      170.5




      -




      -




      170.5




      37.4




      21.9

      %

      Breast Implants



      187.3




      -




      (14.5)




      -




      172.8




      194.8




      -




      119.6




      -




      314.4




      (141.6)




      (45.0)

      %

      Carafate ® /Sulcrate ®



      -




      165.6




      2.1




      -




      167.7




      -




      163.7




      2.1




      -




      165.8




      1.9




      1.1

      %

      Armour Thyroid



      -




      161.1




      -




      -




      161.1




      -




      145.4




      -




      -




      145.4




      15.7




      10.8

      %

      Viberzi®



      -




      138.1




      1.2




      -




      139.3




      -




      127.6




      0.7




      -




      128.3




      11.0




      8.6

      %

      Skin Care



      113.4




      -




      10.4




      -




      123.8




      98.4




      -




      11.6




      -




      110.0




      13.8




      12.5

      %

      Teflaro®



      -




      108.9




      2.3




      -




      111.2




      -




      98.0




      0.6




      -




      98.6




      12.6




      12.8

      %

      Saphris®



      -




      99.0




      -




      -




      99.0




      -




      102.9




      -




      -




      102.9




      (3.9)




      (3.8)

      %

      Asacol®/Delzicol®



      -




      68.2




      27.2




      -




      95.4




      -




      102.9




      35.0




      -




      137.9




      (42.5)




      (30.8)

      %

      Avycaz®



      -




      86.0




      -




      -




      86.0




      -




      70.0




      -




      -




      70.0




      16.0




      22.9

      %

      Coolsculpting® Systems & Add On
      Applicators



      45.9




      -




      33.6




      -




      79.5




      99.5




      -




      21.8




      -




      121.3




      (41.8)




      (34.5)

      %

      Namzaric®



      -




      68.4




      -




      -




      68.4




      -




      93.2




      -




      -




      93.2




      (24.8)




      (26.6)

      %

      Savella®



      -




      67.0




      -




      -




      67.0




      -




      61.4




      -




      -




      61.4




      5.6




      9.1

      %

      Dalvance®



      -




      55.5




      3.6




      -




      59.1




      -




      38.8




      1.3




      -




      40.1




      19.0




      47.4

      %

      Liletta®



      -




      56.6




      -




      -




      56.6




      -




      36.3




      -




      -




      36.3




      20.3




      55.9

      %

      Canasa®/Salofalk®



      -




      24.0




      12.1




      -




      36.1




      -




      130.4




      13.1




      -




      143.5




      (107.4)




      (74.8)

      %

      Rapaflo®



      21.5




      -




      3.5




      -




      25.0




      63.0




      -




      4.6




      -




      67.6




      (42.6)




      (63.0)

      %

      Kybella® /Belkyra®



      21.1




      -




      2.5




      -




      23.6




      24.6




      -




      5.3




      -




      29.9




      (6.3)




      (21.1)

      %

      Namenda®



      -




      19.6




      -




      -




      19.6




      -




      60.3




      -




      -




      60.3




      (40.7)




      (67.5)

      %

      Aczone®



      6.8




      -




      -




      -




      6.8




      54.5




      -




      0.3




      -




      54.8




      (48.0)




      (87.6)

      %

      Other Products Revenues



      200.6




      591.0




      257.1




      30.6




      1,079.3




      235.3




      568.2




      291.1




      36.7




      1,131.3




      (52.0)




      (4.6)

      %

      Total Net Revenues


      $

      4,998.8



      $

      4,224.2



      $

      2,484.3



      $

      30.6




      11,737.9



      $

      5,111.5



      $

      3,925.0



      $

      2,634.5



      $

      36.7




      11,707.7



      $

      30.2




      0.3

      %




















































































































































      1Botox® is comprised of the following:

















































      Botox® Therapeutics



      1,276.2




      -




      286.6




      -




      1,562.8




      1,205.2




      -




      293.7




      -




      1,498.9




      63.9




      4.3

      %

      Botox®  Cosmetics



      719.5




      -




      488.8




      -




      1,208.3




      649.2




      -




      483.4




      -




      1,132.6




      75.7




      6.7

      %


















































       

       

      The following table presents Allergan plc's Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018.


      Table 3


      ALLERGAN PLC


      CONDENSED CONSOLIDATED BALANCE SHEETS


      (Unaudited; in millions)




      September 30,



      December 31,




      2019



      2018




















      Assets









      Cash and cash equivalents


      $

      1,237.5



      $

      880.4


      Marketable securities



      3,318.4




      1,026.9


      Accounts receivable, net



      3,012.3




      2,868.1


      Inventories



      1,083.1




      846.9


      Prepaid expenses and other current assets



      942.3




      819.1


      Assets held for sale



      32.5




      916.2


      Property, plant and equipment, net



      1,857.0




      1,787.0


      Investments and other assets



      855.3




      3,034.3


      Right of use asset - operating leases



      478.2




      -


      Product rights and other intangibles



      39,526.8




      43,695.4


      Goodwill



      42,065.5




      45,913.3


      Total assets


      $

      94,408.9



      $

      101,787.6











      Liabilities & Equity









      Current liabilities


      $

      5,781.1



      $

      4,859.6


      Lease liability



      555.8



      $

      -


      Current and long-term debt and capital leases



      22,525.2




      23,797.7


      Deferred income taxes and other liabilities



      7,048.6




      7,999.3


      Total equity



      58,498.2




      65,131.0


      Total liabilities and equity


      $

      94,408.9



      $

      101,787.6


       

       

      The following table presents Allergan plc's Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2019 and 2018.


      Table 4


      ALLERGAN PLC








      CONSOLIDATED STATEMENTS OF CASH FLOWS








      (Unaudited; in millions)










      Three Months Ended September 30,



      Nine Months Ended September 30,




      2019



      2018



      2019



      2018


      Cash Flows From Operating Activities:

















      Net (loss) / income


      $

      (785.6)



      $

      (36.3)



      $

      (4,947.8)



      $

      (790.3)


      Reconciliation to net cash provided by operating activities:

















      Depreciation



      54.4




      44.5




      150.6




      149.7


      Amortization



      1,537.7




      1,588.5




      4,339.1




      4,983.2


      Provision for inventory reserve



      44.4




      29.5




      127.8




      74.9


      Share-based compensation



      49.9




      57.8




      161.7




      185.2


      Deferred income tax benefit



      (198.9)




      (3.2)




      (365.3)




      (1,362.8)


      In-process research and development impairments



      -




      -




      436.0




      798.0


      Loss on asset sales and impairments, net



      2.0




      (0.4)




      3,679.0




      272.3


      Gain on forward sale of Teva shares



      -




      -




      -




      (60.9)


      Gain on sale of businesses



      -




      (129.6)




      -




      (182.6)


      Non-cash extinguishment of debt



      -




      13.4




      0.2




      17.4


      Cash charge related to extinguishment of debt



      -




      (5.1)




      -




      (18.2)


      Amortization of deferred financing costs



      4.2




      5.5




      13.3




      17.4


      Non-cash lease expense



      25.5




      -




      93.5




      -


      Contingent consideration adjustments,
         including accretion



      2.7




      (11.3)




      49.5




      (113.1)


      Other, net



      17.0




      0.8




      (2.3)




      0.5


      Changes in assets and liabilities (net of effects
         of acquisitions):

















      Decrease / (increase) in accounts receivable, net



      36.0




      (73.3)




      (184.6)




      17.0


      Decrease / (increase) in inventories



      (149.6)




      (22.9)




      (328.9)




      (136.2)


      Decrease / (increase) in prepaid expenses
         and other current assets



      (60.1)




      (44.7)




      (36.2)




      (5.4)


      Increase / (decrease) in accounts payable
         and accrued expenses



      713.3




      (5.7)




      874.9




      (46.1)


      Increase / (decrease) in income and other
         taxes payable



      1,682.9




      50.1




      1,638.7




      415.5


      Increase / (decrease) in other assets and liabilities



      (51.7)




      (14.6)




      (130.8)




      (74.0)


      Net cash provided by operating activities



      2,924.1




      1,443.0




      5,568.4




      4,141.5


      Cash Flows From Investing Activities:

















      Additions to property, plant and equipment



      (101.0)




      (58.6)




      (253.3)




      (165.1)


      Additions to product rights and other intangibles



      -




      -




      (46.0)




      -


      Additions to investments



      (2,999.8)




      (0.5)




      (3,738.0)




      (1,456.4)


      Proceeds from sale of investments and other assets



      4.7




      550.0




      1,466.7




      6,201.3


      Payments to settle Teva related matters



      -




      -




      -




      (466.0)


      Proceeds from sales of property, plant and equipment



      0.8




      13.1




      18.5




      24.6


      Acquisitions of businesses, net of cash acquired



      -




      -




      (80.6)




      -


      Net cash (used in) / provided by investing activities



      (3,095.3)




      504.0




      (2,632.7)




      4,138.4


      Cash Flows From Financing Activities:

















      Proceeds from borrowings on long-term indebtedness, including credit

         facility



      -




      8.2




      3.3




      717.2


      Proceeds from Forward Sale of Teva securities



      -




      -




      -




      465.5


      Payments on debt, including capital lease obligations



      (5.8)




      (1,762.2)




      (1,044.9)




      (7,115.9)


      Proceeds from stock plans



      21.4




      29.0




      45.0




      98.2


      Other financing, including contingent consideration



      (2.2)




      (11.1)




      (6.3)




      (21.7)


      Payments to settle Teva related matters



      -




      -




      -




      (234.0)


      Repurchase of ordinary shares



      (0.8)




      (451.4)




      (834.3)




      (2,023.5)


      Dividends



      (242.6)




      (244.4)




      (731.4)




      (808.1)


      Net cash (used in) financing activities



      (230.0)




      (2,431.9)




      (2,568.6)




      (8,922.3)


      Effect of currency exchange rate changes on cash

         and cash equivalents



      (12.7)




      (1.9)




      (10.0)




      13.1


      Net increase / (decrease) in cash and cash equivalents



      (413.9)




      (486.8)




      357.1




      (629.3)


      Cash and cash equivalents at beginning of period



      1,651.4




      1,674.7




      880.4




      1,817.2


      Cash and cash equivalents at end of period


      $

      1,237.5



      $

      1,187.9



      $

      1,237.5



      $

      1,187.9


       


       

      Non-GAAP performance net income per share is used by management as one of the primary metrics in evaluating the Company's performance.  We believe that Non-GAAP performance net income per share enhances the comparability of our results between periods and provides additional information and transparency to investors on adjustments and other items that are not indicative of the Company's current and future operating performance.  These are the financial measures used by our management team to evaluate our operating performance and make day to day operating decisions.  We define non-GAAP adjustments to the reported GAAP measures as GAAP results adjusted for the following net of tax: (i) amortization expenses, (ii) global supply chain and operational excellence initiatives or other restructurings of a similar nature, (iii) acquisition, divestiture, integration and licensing charges, (iv) accretion and fair market value adjustments on contingent liabilities, (v) impairment/asset sales and related costs, including the exclusion of discontinued operations, (vi) legal settlements and (vii) other unusual charges or expenses.  Non-GAAP performance net income per share is not, and should not be viewed as, a substitute for reported GAAP continuing operations loss per share.  The Company has consistently excluded amortization of all intangible assets, including the product rights that generate a significant portion of our ongoing revenue. The Company's total accumulated amortization, including impairments of currently marketed products, related to our intangible assets as of September 30, 2019 and December 31, 2018 was $37.7 billion and $32.9 billion, respectively, and is expected to continue to be a material non-GAAP adjustment.  The following table presents Allergan plc's GAAP to Non-GAAP adjustments for the three and nine months ended September 30, 2019 and 2018:


      Table 5


      ALLERGAN PLC


      GAAP TO NON-GAAP ADJUSTMENTS


      (Unaudited; in millions)













































      Three Months Ended September 30, 2019




      Net

      Revenue



      COGS



      Research &

      Development



      Selling &

      Marketing



      General &

      Administrative



      Amortization



      Asset sales &
      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      4,050.7



      $

      639.0



      $

      474.5



      $

      901.4



      $

      1,092.7



      $

      1,537.7



      $

      2.0



      $

      (173.4)



      $

      2.5



      $

      18.1











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.2)




      (0.2)




      (0.6)




      (0.2)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (1.1)




      0.8




      (3.5)




      (6.3)




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      0.1




      -




      (0.7)




      (1.7)




      -




      -




      -




      -




      -


      Costs associated with the AbbVie transaction



      -




      (0.5)




      (1.9)




      (18.7)




      (32.7)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      RetroSense Therapeutics, LLC



      -




      -




      (20.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (2.0)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (0.4)




      (2.3)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (5.4)




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      (2.0)




      -




      -




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (747.5)




      -




      -




      -




      -




      -


      Milestone component of ongoing intellectual property
      agreement



      (25.0)




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Other adjustments



      -




      -




      -




      -




      (2.8)




      (1,537.7)




      -




      -




      -




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      307.7


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      (147.8)











































      Non-GAAP Adjusted


      $

      4,025.7



      $

      636.9



      $

      448.9



      $

      877.9



      $

      301.5



      $

      -



      $

      -



      $

      (178.8)



      $

      2.5



      $

      178.0










































































































































































































































































































































































































































































































































































































































































































































































































































































































































      Three Months Ended September 30, 2018




      Net

      Revenue



      COGS



      Research &
      Development



      Selling &
      Marketing



      General &
      Administrative



      Amortization



      Asset sales &
      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      3,911.4



      $

      596.8



      $

      424.2



      $

      755.6



      $

      289.2



      $

      1,588.5



      $

      (0.4)



      $

      (210.4)



      $

      130.0



      $

      213.4











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.3)




      (0.6)




      (1.2)




      (0.4)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (6.6)




      (0.9)




      (1.3)




      (1.3)




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      -




      -




      -




      0.5




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.2)




      (0.2)




      (0.3)




      (8.5)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Merck & Co.



      -




      -




      (30.0)




      -




      -




      -




      -




      -




      -




      -


      Editas Medicine, Inc.



      -




      -




      (15.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (5.1)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (10.0)




      21.4




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (5.5)




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      0.4




      -




      -




      -


      Gain on the sale of divestiture



      -




      -




      -




      -




      -




      -




      -




      -




      (129.6)




      -


      Loss on bond repurchases



      -




      -




      -




      -




      -




      -




      -




      -




      7.5




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (1.1)




      -




      -




      -




      -




      -


      Other adjustments



      -




      (0.1)




      (0.1)




      -




      0.2




      (1,588.5)




      -




      -




      (3.9)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      94.2


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      (67.6)











































      Non-GAAP Adjusted


      $

      3,911.4



      $

      579.6



      $

      393.7



      $

      752.8



      $

      278.6



      $

      -



      $

      -



      $

      (215.9)



      $

      4.0



      $

      240.0











































      The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the three months ended September 30, 2019 was impacted by U.S. income taxed at rates higher than the Irish statutory rate, partially offset by income earned in jurisdictions with tax rates lower than the Irish statutory rate.

       

      The non-GAAP effective tax rate for the three months ended September 30, 2019 excludes a net discrete tax detriment of $147.8 million related to a change in a valuation allowance partially offset by changes in the applicable tax rates on certain temporary differences.
























































































































































































































































































































































































































































































































































































































































































































































































































































      Nine Months Ended September 30, 2019




      Net

      Revenue



      COGS



      Research &

      Development



      Selling &

      Marketing



      General &

      Administrative



      Amortization



      Asset sales &
      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      11,737.9



      $

      1,789.1



      $

      1,359.5



      $

      2,578.7



      $

      1,725.2



      $

      4,339.1



      $

      4,115.0



      $

      (539.6)



      $

      11.6



      $

      251.1











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (0.7)




      (0.9)




      (2.2)




      (0.7)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      -




      (0.8)




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (6.0)




      0.8




      (2.6)




      (8.5)




      -




      -




      -




      -




      -


      Costs associated with disposed businesses



      -




      -




      -




      -




      (0.3)




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      0.1




      (0.5)




      (0.8)




      (10.0)




      -




      -




      -




      -




      -


      Costs associated with the AbbVie transaction



      -




      (0.5)




      (1.9)




      (18.7)




      (52.2)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Akarna Therapeutics, Ltd



      -




      -




      (10.0)




      -




      -




      -




      -




      -




      -




      -


      RetroSense Therapeutics, LLC



      -




      -




      (20.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (26.1)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      (42.4)




      (7.1)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (16.4)




      -




      -


      Impairment of goodwill



      -




      -




      -




      -




      -




      -




      (3,552.8)




      -




      -




      -


      Impairment of Anti-Infectives



      -




      -




      -




      -




      -




      -




      (129.4)




      -




      -




      -


      Impairment of IPR&D products acquired in the Allergan
      Acquisition



      -




      -




      -




      -




      -




      -




      (182.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Vitae
      Acquisition



      -




      -




      -




      -




      -




      -




      (78.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Tobira
      Acquisition



      -




      -




      -




      -




      -




      -




      (176.0)




      -




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      3.2




      -




      -




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (765.7)




      -




      -




      -




      -




      -


      Milestone component of ongoing intellectual property
      agreement



      (25.0)




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Other adjustments



      -




      (0.1)




      -




      -




      (3.0)




      (4,339.1)




      -




      -




      (0.3)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      782.4


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      (457.0)











































      Non-GAAP Adjusted


      $

      11,712.9



      $

      1,739.5



      $

      1,293.8



      $

      2,554.4



      $

      884.0



      $

      -



      $

      -



      $

      (556.0)



      $

      11.3



      $

      576.5




















































































































































































































































































































































































































































































































































































































































































      Nine Months Ended September 30, 2018




      Net

      Revenue



      COGS



      Research &
      Development



      Selling &
      Marketing



      General &
      Administrative



      Amortization



      Asset sales &
      Impairments,
      net



      Interest

      expense,

      net



      Other

      income

      (expense)



      Income

      taxes


      GAAP


      $

      11,707.7



      $

      1,601.4



      $

      1,588.1



      $

      2,409.0



      $

      919.2



      $

      4,983.2



      $

      1,070.3



      $

      (667.4)



      $

      266.6



      $

      (474.0)











































      Purchase accounting impact on stock-based compensation for
      acquired awards



      -




      (1.8)




      (4.2)




      (7.2)




      (2.5)




      -




      -




      -




      -




      -


      Severance due to integration of acquired entities



      -




      -




      -




      (0.7)




      (0.8)




      -




      -




      -




      -




      -


      Non-acquisition related severance and restructuring



      -




      (28.5)




      (1.8)




      (18.5)




      (5.6)




      -




      (13.6)




      -




      -




      -


      Costs associated with disposed businesses



      -




      (1.5)




      -




      -




      (2.8)




      -




      -




      -




      -




      -


      Integration charges of acquired businesses



      -




      (0.2)




      (0.8)




      (1.0)




      (33.1)




      -




      -




      -




      -




      -


      Milestones and upfront expenses for asset acquisitions









































      Elastagen Pty Ltd



      -




      -




      (96.1)




      -




      -




      -




      -




      -




      -




      -


      AstraZeneca plc



      -




      -




      (90.0)




      -




      -




      -




      -




      -




      -




      -


      Merck & Co.



      -




      -




      (115.0)




      -




      -




      -




      -




      -




      -




      -


      Chase Pharmaceuticals Corporation



      -




      -




      (75.0)




      -




      -




      -




      -




      -




      -




      -


      Repros Therapeutics, Inc.



      -




      -




      (33.2)




      -




      -




      -




      -




      -




      -




      -


      Editas Medicine, Inc.



      -




      -




      (15.0)




      -




      -




      -




      -




      -




      -




      -


      Other



      -




      -




      (16.5)




      -




      -




      -




      -




      -




      -




      -


      Accretion and fair-value adjustments to contingent
      consideration



      -




      115.4




      (2.2)




      -




      -




      -




      -




      -




      -




      -


      Non-cash amortization of debt premium recognized in
      purchase accounting



      -




      -




      -




      -




      -




      -




      -




      (15.7)




      -




      -


      Impairment of IPR&D products acquired in the Allergan
      Acquisition



      -




      -




      -




      -




      -




      -




      (236.0)




      -




      -




      -


      Impairment of IPR&D products acquired in the Vitae
      Acquisition



      -




      -




      -




      -




      -




      -




      (40.0)




      -




      -




      -


      Impairment of assets held for sale



      -




      -




      -




      -




      -




      -




      (252.0)




      -




      -




      -


      Impairment of RORgt IPR&D product



      -




      -




      -




      -




      -




      -




      (522.0)




      -




      -




      -


      Asset sales and impairments, other



      -




      -




      -




      -




      -




      -




      (6.7)




      -




      -




      -


      Gain on Teva securities



      -




      -




      -




      -




      -




      -




      -




      -




      (60.6)




      -


      Milestone component of ongoing intellectual property
      agreement



      (25.0)




      -




      -




      -




      -




      -




      -




      -




      -




      -


      Gain on the sale of divestiture



      -




      -




      -




      -




      -




      -




      -




      -




      (182.6)




      -


      Gain on bond repurchases



      -




      -




      -




      -




      -




      -




      -




      -




      (1.7)




      -


      Litigation settlement related charges



      -




      -




      -




      -




      (40.4)




      -




      -




      -




      -




      -


      Other adjustments



      -




      -




      0.1




      -




      (1.1)




      (4,983.2)




      -




      -




      (3.7)




      -


      Income taxes on pre-tax adjustments



      -




      -




      -




      -




      -




      -




      -




      -




      -




      847.3


      Discrete income tax events



      -




      -




      -




      -




      -




      -




      -




      -




      -




      334.0











































      Non-GAAP Adjusted


      $

      11,682.7



      $

      1,684.8



      $

      1,138.4



      $

      2,381.6



      $

      832.9



      $

      -



      $

      -



      $

      (683.1)



      $

      18.0



      $

      707.3











































      The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the nine months ended September 30, 2019 was impacted by U.S. income taxed at rates higher than the Irish statutory rate, partially offset by income earned in jurisdictions with tax rates lower than the Irish statutory rate.

       

      The non-GAAP effective tax rate for the nine months ended September 30, 2019 excludes a net discrete tax detriment of $457.0 million related to a change in a valuation allowance and uncertain tax positions offset by the tax effects of intangible asset impairments, U.S. capital losses and changes in the applicable tax rates on certain temporary differences.












































       

       

      The following table presents a reconciliation of Allergan plc's reported net income / (loss) from continuing operations attributable to shareholders and diluted earnings per share to non-GAAP performance net income and non-GAAP performance net income per share for the three and nine months ended September 30, 2019 and 2018:


      Table 6


      ALLERGAN PLC








      RECONCILIATION TABLE








      (Unaudited; in millions except per share amounts)



























      Three Months Ended



      Nine Months Ended




      September 30,



      September 30,




      2019



      2018



      2019



      2018




































      GAAP to Non-GAAP Performance net income calculation


































      GAAP (loss) from continuing operations attributable to
      shareholders


      $

      (786.8)



      $

      (37.9)



      $

      (4,953.8)



      $

      (796.5)


      Adjusted for:

















      Amortization



      1,537.7




      1,588.5




      4,339.1




      4,983.2


      Acquisition, divestiture and licensing (income) /
      charges



      51.7




      (77.7)




      107.6




      235.8


      Accretion and fair-value adjustments to contingent
      consideration



      2.7




      (11.4)




      49.5




      (113.2)


      Goodwill and other impairments and asset sales, net
      and related costs



      2.0




      (0.4)




      4,115.0




      1,070.3


      Other



      -




      7.5




      -




      (26.7)


      Non-acquisition restructurings, including Global Supply
      Chain initiatives



      10.1




      10.1




      16.3




      54.4


      Legal settlements



      747.5




      1.1




      765.7




      40.4


      Income taxes on items above and other discrete
      income tax adjustments



      (159.9)




      (26.6)




      (325.4)




      (1,181.3)


      Non-GAAP performance net income attributable to
      shareholders


      $

      1,405.0



      $

      1,453.2



      $

      4,114.0



      $

      4,266.4



















      Diluted earnings per share


































      Diluted (loss) / income per share from continuing
      operations attributable to shareholders- GAAP


      $

      (2.40)



      $

      (0.11)



      $

      (15.04)



      $

      (2.36)



















      Non-GAAP performance net income per share attributable
      to shareholders


      $

      4.25



      $

      4.25



      $

      12.43



      $

      12.41



















      Basic weighted average ordinary shares outstanding



      328.0




      339.0




      329.3




      337.6


      Effect of dilutive securities:

















      Dilutive shares



      2.2




      2.7




      1.8




      6.2


      Diluted weighted average ordinary shares outstanding



      330.2




      341.7




      331.1




      343.8


















       

       

      We define adjusted EBITDA as an amount equal to consolidated net income / (loss) from continuing operations attributable to shareholders for such period adjusted for the following: (i) interest expense, (ii) interest income, (iii) (benefit) for income taxes, (iv) depreciation and amortization expenses, (v) stock-based compensation expense, (vi) asset impairment charges and losses / (gains) and expenses associated with the sale of assets, including the exclusion of discontinued operations, (vii) business restructuring charges associated with Allergan's global supply chain and operational excellence initiatives or other restructurings of a similar nature, (viii) costs and charges associated with the acquisition and divestitures of businesses and assets including, but not limited to, milestone payments, integration charges, other charges associated with the revaluation of assets or liabilities and charges associated with the revaluation of acquisition related contingent liabilities that are based in whole or in part on future estimated cash flows, (ix) litigation charges and settlements and (x) other unusual charges or expenses. We define non-GAAP adjusted operating income as adjusted EBITDA including depreciation and certain stock-based compensation charges and excluding dividend income and fair value accounting results included within other income (expense), net.

       

      The following table presents a reconciliation of Allergan plc's reported net income / (loss) from continuing operations attributable to shareholders for the three and nine months ended September 30, 2019 and 2018 to adjusted EBITDA and non-GAAP operating income:


      Table 7


      ALLERGAN PLC








      ADJUSTED EBITDA and NON-GAAP OPERATING INCOME, RECONCILIATION TABLE








      (Unaudited; in millions)


















      Three Months Ended



      Nine Months Ended




      September 30,



      September 30,




      2019



      2018



      2019



      2018




































      GAAP (loss) from continuing operations attributable to
      shareholders


      $

      (786.8)



      $

      (37.9)



      $

      (4,953.8)



      $

      (796.5)


      Plus:

















      Interest expense



      193.9




      220.4




      591.1




      701.0


      Interest income



      (20.5)




      (10.0)




      (51.5)




      (33.6)


      Provision / (benefit) for income taxes



      18.1




      213.4




      251.1




      (474.0)


      Depreciation



      54.4




      44.5




      150.6




      149.7


      Amortization



      1,537.7




      1,588.5




      4,339.1




      4,983.2


      EBITDA


      $

      996.8



      $

      2,018.9



      $

      326.6



      $

      4,529.8


      Adjusted for:

















      Acquisition, divestiture and licensing charges



      55.9




      (74.7)




      119.5




      227.6


      Goodwill and other impairments and asset sales, net and
      related costs



      2.0




      (0.4)




      4,115.0




      1,070.3


      Other



      -




      7.5




      -




      (26.7)


      Non-acquisition restructurings, including Global Supply Chain
      initiatives, excluding depreciation



      10.1




      8.9




      16.3




      50.2


      Legal settlements



      747.5




      1.1




      765.7




      40.4


      Accretion and fair-value adjustments to contingent
      consideration



      2.7




      (11.4)




      49.5




      (113.2)


      Share-based compensation including cash settlements



      49.9




      57.8




      161.7




      185.2


      Adjusted EBITDA


      $

      1,864.9



      $

      2,007.7



      $

      5,554.3



      $

      5,963.6


      Adjusted for:

















      Depreciation



      (54.4)




      (43.3)




      (150.6)




      (145.5)


      Other income (expense) related to fair value accounting



      (2.5)




      (4.0)




      (11.3)




      (18.8)


      Share-based compensation not related to restructuring
      charges and purchase accounting impact on stock-based
      compensation for acquired awards



      (48.7)




      (55.3)




      (157.2)




      (161.3)


      Non-GAAP Operating Income


      $

      1,759.3



      $

      1,905.1



      $

      5,235.2



      $

      5,638.0


       

       

      The following table details Allergan plc's segment contribution reconciled to the non-GAAP contribution for the same financial statement line items for the three and nine months ended September 30, 2019 and 2018.





































































































      Table 8


      ALLERGAN PLC


      Segment Contribution to Non-GAAP Allergan plc Contribution


      (Unaudited; $ in millions)













































      Three Months Ended September 30, 2019



      Three Months Ended September 30, 2018



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total


      Net revenues

      $

      1,670.8



      $

      1,518.6



      $

      835.1



      $

      1.2



      $

      4,025.7



      $

      1,706.2



      $

      1,381.3



      $

      821.6



      $

      2.3



      $

      3,911.4


      Operating expenses:








































      Cost of sales(1)


      151.1




      245.2




      144.6




      96.0




      636.9




      143.0




      219.6




      130.7




      86.3




      579.6


      Selling and marketing


      389.5




      261.2




      226.9




      0.3




      877.9




      313.7




      233.2




      206.0




      (0.1)




      752.8


      General and administrative


      50.1




      45.0




      26.0




      180.4




      301.5




      47.3




      37.7




      35.1




      158.5




      278.6


      Segment contribution

      $

      1,080.1



      $

      967.2



      $

      437.6



      $

      (275.5)



      $

      2,209.4



      $

      1,202.2



      $

      890.8



      $

      449.8



      $

      (242.4)



      $

      2,300.4


      Segment margin


      64.6

      %



      63.7

      %



      52.4

      %


      n.m.




      54.9

      %



      70.5

      %



      64.5

      %



      54.7

      %


      n.m.




      58.8

      %

      Segment gross margin(2)


      91.0

      %



      83.9

      %



      82.7

      %


      n.m.




      84.2

      %



      91.6

      %



      84.1

      %



      84.1

      %


      n.m.




      85.2

      %










































      (1) Excludes amortization and impairment of acquired intangibles including product rights.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.













































      Nine Months Ended September 30, 2019



      Nine Months Ended September 30, 2018



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total



      US Specialized

      Therapeutics

      Segment



      US General

      Medicine Segment



      International

      Segment



      Corporate



      Total


      Net revenues

      $

      4,998.8



      $

      4,224.2



      $

      2,484.3



      $

      5.6



      $

      11,712.9



      $

      5,111.5



      $

      3,925.0



      $

      2,634.5



      $

      11.7



      $

      11,682.7


      Operating expenses:








































      Cost of sales(1)


      422.2




      667.0




      399.9




      250.4




      1,739.5




      425.9




      604.0




      391.0




      263.9




      1,684.8


      Selling and marketing


      1,114.3




      721.8




      718.1




      0.2




      2,554.4




      970.2




      713.5




      697.9




      -




      2,381.6


      General and administrative


      142.3




      119.2




      80.1




      542.4




      884.0




      145.6




      111.3




      100.4




      475.6




      832.9


      Segment contribution

      $

      3,320.0



      $

      2,716.2



      $

      1,286.2



      $

      (787.4)



      $

      6,535.0



      $

      3,569.8



      $

      2,496.2



      $

      1,445.2



      $

      (727.8)



      $

      6,783.4


      Segment margin


      66.4

      %



      64.3

      %



      51.8

      %


      n.m.




      55.8

      %



      69.8

      %



      63.6

      %



      54.9

      %


      n.m.




      58.1

      %

      Segment gross margin(2)


      91.6

      %



      84.2

      %



      83.9

      %


      n.m.




      85.1

      %



      91.7

      %



      84.6

      %



      85.2

      %


      n.m.




      85.6

      %










































      (1) Excludes amortization and impairment of acquired intangibles including product rights.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.











































       


       

      The following table details Allergan plc's product revenue for significant promoted products within the US Specialized Therapeutics segment for the three and nine months ended September 30, 2019 and 2018.


      Table 9


      ALLERGAN PLC


      US Specialized Therapeutics Product Revenue


      (Unaudited; in millions)
















      Three Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      558.3



      $

      570.3



      $

      (12.0)




      (2.1)

      %

      Restasis®



      286.8




      298.0




      (11.2)




      (3.8)

      %

      Alphagan®/Combigan®



      90.9




      95.4




      (4.5)




      (4.7)

      %

      Lumigan®/Ganfort®



      67.5




      78.0




      (10.5)




      (13.5)

      %

      Ozurdex®



      33.7




      28.6




      5.1




      17.8

      %

      Eye Drops



      62.0




      54.8




      7.2




      13.1

      %

      Other Eye Care



      17.4




      15.5




      1.9




      12.3

      %

      Total Medical Aesthetics



      646.1




      657.1




      (11.0)




      (1.7)

      %

      Facial Aesthetics



      377.7




      348.4




      29.3




      8.4

      %

      Botox®Cosmetics



      237.6




      216.0




      21.6




      10.0

      %

      Juvederm®Collection



      134.8




      127.2




      7.6




      6.0

      %

      Kybella®



      5.3




      5.2




      0.1




      1.9

      %

      Plastic Surgery



      58.5




      58.2




      0.3




      0.5

      %

      Breast Implants



      58.5




      58.2




      0.3




      0.5

      %

      Regenerative Medicine



      120.8




      133.4




      (12.6)




      (9.4)

      %

      Alloderm®



      95.0




      105.8




      (10.8)




      (10.2)

      %

      Other Regenerative Medicine



      25.8




      27.6




      (1.8)




      (6.5)

      %

      Body Contouring



      53.0




      84.9




      (31.9)




      (37.6)

      %

      Coolsculpting®Systems & Add On
      Applicators



      12.6




      29.4




      (16.8)




      (57.1)

      %

      Coolsculpting®Consumables



      40.4




      55.5




      (15.1)




      (27.2)

      %

      Skin Care(3)



      36.1




      32.2




      3.9




      12.1

      %

      Total Medical Dermatology



      15.6




      35.1




      (19.5)




      (55.6)

      %

      Aczone®



      3.4




      17.4




      (14.0)




      (80.5)

      %

      Other Medical Dermatology(4)



      12.2




      17.7




      (5.5)




      (31.1)

      %

      Total Neuroscience & Urology



      436.8




      427.9




      8.9




      2.1

      %

      Botox®Therapeutics



      431.6




      407.4




      24.2




      5.9

      %

      Rapaflo®



      5.2




      20.5




      (15.3)




      (74.6)

      %

      Other Revenues



      14.0




      15.8




      (1.8)




      (11.4)

      %

      Net Revenues


      $

      1,670.8



      $

      1,706.2



      $

      (35.4)




      (2.1)

      %


















      Operating expenses:

















      Cost of sales(1)



      151.1




      143.0




      8.1




      5.7

      %

      Selling and marketing



      389.5




      313.7




      75.8




      24.2

      %

      General and administrative



      50.1




      47.3




      2.8




      5.9

      %

      Segment contribution


      $

      1,080.1



      $

      1,202.2



      $

      (122.1)




      (10.2)

      %

      Segment margin



      64.6

      %



      70.5

      %







      (5.9)

      %

      Segment gross margin(2)



      91.0

      %



      91.6

      %







      (0.6)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes SkinMedica® and Latisse®.


      (4) Includes Tazorac® sales of $9.3 million which were previously disclosed separately in the three months ended September 30, 2018.
























































































































































      Nine Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      1,595.4



      $

      1,648.4



      $

      (53.0)




      (3.2)

      %

      Restasis®



      829.4




      872.0




      (42.6)




      (4.9)

      %

      Alphagan®/Combigan®



      265.5




      277.7




      (12.2)




      (4.4)

      %

      Lumigan®/Ganfort®



      187.3




      217.8




      (30.5)




      (14.0)

      %

      Ozurdex®



      93.9




      81.7




      12.2




      14.9

      %

      Eye Drops



      169.2




      154.8




      14.4




      9.3

      %

      Other Eye Care



      50.1




      44.4




      5.7




      12.8

      %

      Total Medical Aesthetics



      2,029.8




      2,036.3




      (6.5)




      (0.3)

      %

      Facial Aesthetics



      1,161.7




      1,063.6




      98.1




      9.2

      %

      Botox®Cosmetics



      719.5




      649.2




      70.3




      10.8

      %

      Juvederm®Collection



      421.1




      389.8




      31.3




      8.0

      %

      Kybella®



      21.1




      24.6




      (3.5)




      (14.2)

      %

      Plastic Surgery



      187.3




      194.8




      (7.5)




      (3.9)

      %

      Breast Implants



      187.3




      194.8




      (7.5)




      (3.9)

      %

      Regenerative Medicine



      372.6




      399.2




      (26.6)




      (6.7)

      %

      Alloderm®



      291.2




      312.4




      (21.2)




      (6.8)

      %

      Other Regenerative Medicine



      81.4




      86.8




      (5.4)




      (6.2)

      %

      Body Contouring



      194.8




      280.3




      (85.5)




      (30.5)

      %

      Coolsculpting®Systems & Add On
      Applicators



      45.9




      99.5




      (53.6)




      (53.9)

      %

      Coolsculpting®Consumables



      148.9




      180.8




      (31.9)




      (17.6)

      %

      Skin Care(3)



      113.4




      98.4




      15.0




      15.2

      %

      Total Medical Dermatology



      31.0




      111.0




      (80.0)




      (72.1)

      %

      Aczone®



      6.8




      54.5




      (47.7)




      (87.5)

      %

      Other Medical Dermatology(4)



      24.2




      56.5




      (32.3)




      (57.2)

      %

      Total Neuroscience & Urology



      1,297.7




      1,268.2




      29.5




      2.3

      %

      Botox®Therapeutics



      1,276.2




      1,205.2




      71.0




      5.9

      %

      Rapaflo®



      21.5




      63.0




      (41.5)




      (65.9)

      %

      Other Revenues



      44.9




      47.6




      (2.7)




      (5.7)

      %

      Net Revenues


      $

      4,998.8



      $

      5,111.5



      $

      (112.7)




      (2.2)

      %


















      Operating expenses:

















      Cost of sales(1)



      422.2




      425.9




      (3.7)




      (0.9)

      %

      Selling and marketing



      1,114.3




      970.2




      144.1




      14.9

      %

      General and administrative



      142.3




      145.6




      (3.3)




      (2.3)

      %

      Segment contribution


      $

      3,320.0



      $

      3,569.8



      $

      (249.8)




      (7.0)

      %

      Segment margin



      66.4

      %



      69.8

      %







      (3.4)

      %

      Segment gross margin(2)



      91.6

      %



      91.7

      %







      (0.1)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes SkinMedica® and Latisse®.


      (4) Includes Tazorac® sales of $25.1 million which were previously disclosed separately in the six months ended September 30, 2018.




       

      The following table details Allergan plc's product revenue for significant promoted products within the US General Medicine segment for the three and nine months ended September 30, 2019 and 2018.


      Table 10


      ALLERGAN PLC


      US General Medicine Product Revenue


      (Unaudited; in millions)
















      Three Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Central Nervous System (CNS)


      $

      400.6



      $

      307.2



      $

      93.4




      30.4

      %

      Vraylar®



      234.6




      138.0




      96.6




      70.0

      %

      Viibryd®/Fetzima®



      105.1




      88.5




      16.6




      18.8

      %

      Saphris®



      34.5




      36.4




      (1.9)




      (5.2)

      %

      Namzaric®



      22.4




      28.0




      (5.6)




      (20.0)

      %

      Namenda ®(3)



      4.0




      16.3




      (12.3)




      (75.5)

      %

      Total Gastrointestinal (GI)



      422.7




      453.3




      (30.6)




      (6.8)

      %

      Linzess®



      214.7




      204.8




      9.9




      4.8

      %

      Zenpep®



      74.2




      62.1




      12.1




      19.5

      %

      Carafate®/Sulcrate®



      55.1




      53.4




      1.7




      3.2

      %

      Viberzi®



      50.1




      46.8




      3.3




      7.1

      %

      Asacol®/Delzicol®



      11.9




      32.1




      (20.2)




      (62.9)

      %

      Canasa®/Salofalk®



      5.8




      46.8




      (41.0)




      (87.6)

      %

      Other GI



      10.9




      7.3




      3.6




      49.3

      %

      Total Women's Health



      235.9




      213.1




      22.8




      10.7

      %

      Lo Loestrin®



      161.4




      141.5




      19.9




      14.1

      %

      Liletta®



      19.9




      12.7




      7.2




      56.7

      %

      Other Women's Health(4)(5)



      54.6




      58.9




      (4.3)




      (7.3)

      %

      Total Anti-Infectives



      99.8




      74.2




      25.6




      34.5

      %

      Teflaro®



      38.4




      33.4




      5.0




      15.0

      %

      Avycaz®



      29.6




      24.7




      4.9




      19.8

      %

      Dalvance®



      23.2




      9.2




      14.0




      152.2

      %

      Other Anti-Infectives



      8.6




      6.9




      1.7




      24.6

      %

      Diversified Brands



      305.6




      296.1




      9.5




      3.2

      %

      Bystolic®/Byvalson®



      152.2




      151.2




      1.0




      0.7

      %

      Armour Thyroid



      54.4




      48.0




      6.4




      13.3

      %

      Savella®



      24.0




      22.4




      1.6




      7.1

      %

      Other Diversified Brands(6)(7)



      75.0




      74.5




      0.5




      0.7

      %

      Other Revenues



      54.0




      37.4




      16.6




      44.4

      %

      Net revenues


      $

      1,518.6



      $

      1,381.3



      $

      137.3




      9.9

      %


















      Operating expenses:

















      Cost of sales(1)



      245.2




      219.6




      25.6




      11.7

      %

      Selling and marketing



      261.2




      233.2




      28.0




      12.0

      %

      General and administrative



      45.0




      37.7




      7.3




      19.4

      %

      Segment contribution


      $

      967.2



      $

      890.8



      $

      76.4




      8.6

      %

      Segment margin



      63.7

      %



      64.5

      %







      (0.8)

      %

      Segment gross margin(2)



      83.9

      %



      84.1

      %







      (0.2)

      %

      (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Namenda XR® and Namenda® IR.


      (4) Includes Estrace® Cream sales of $14.8 million which were previously disclosed separately in the three months ended September 30, 2018


      (5) Includes Minastrin® 24 sales of $0.6 million which were previously disclosed separately in the three months ended September 30, 2018


      (6) Includes Lexapro® sales of $15.6 million which were previously disclosed separately in the three months ended September 30, 2018


      (7) Includes PacPharma sales of $2.5 million which were previously disclosed separately in the three months ended September 30, 2018

























































































      Nine Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Central Nervous System (CNS)


      $

      1,059.3



      $

      839.9



      $

      219.4




      26.1

      %

      Vraylar®



      574.4




      336.6




      237.8




      70.6

      %

      Viibryd®/Fetzima®



      297.9




      246.9




      51.0




      20.7

      %

      Saphris®



      99.0




      102.9




      (3.9)




      (3.8)

      %

      Namzaric®



      68.4




      93.2




      (24.8)




      (26.6)

      %

      Namenda ®(3)



      19.6




      60.3




      (40.7)




      (67.5)

      %

      Total Gastrointestinal (GI)



      1,200.1




      1,273.9




      (73.8)




      (5.8)

      %

      Linzess®



      572.0




      555.9




      16.1




      2.9

      %

      Zenpep®



      207.2




      170.5




      36.7




      21.5

      %

      Carafate®/Sulcrate®



      165.6




      163.7




      1.9




      1.2

      %

      Viberzi®



      138.1




      127.6




      10.5




      8.2

      %

      Asacol®/Delzicol®



      68.2




      102.9




      (34.7)




      (33.7)

      %

      Canasa®/Salofalk®



      24.0




      130.4




      (106.4)




      (81.6)

      %

      Other GI



      25.0




      22.9




      2.1




      9.2

      %

      Total Women's Health



      662.9




      572.9




      90.0




      15.7

      %

      Lo Loestrin®



      432.7




      383.9




      48.8




      12.7

      %

      Liletta®



      56.6




      36.3




      20.3




      55.9

      %

      Other Women's Health(4)(5)



      173.6




      152.7




      20.9




      13.7

      %

      Total Anti-Infectives



      272.8




      225.6




      47.2




      20.9

      %

      Teflaro®



      108.9




      98.0




      10.9




      11.1

      %

      Avycaz®



      86.0




      70.0




      16.0




      22.9

      %

      Dalvance®



      55.5




      38.8




      16.7




      43.0

      %

      Other Anti-Infectives



      22.4




      18.8




      3.6




      19.1

      %

      Diversified Brands



      882.5




      855.9




      26.6




      3.1

      %

      Bystolic®/Byvalson®



      431.0




      432.1




      (1.1)




      (0.3)

      %

      Armour Thyroid



      161.1




      145.4




      15.7




      10.8

      %

      Savella®



      67.0




      61.4




      5.6




      9.1

      %

      Other Diversified Brands(6)(7)



      223.4




      217.0




      6.4




      2.9

      %

      Other Revenues



      146.6




      156.8




      (10.2)




      (6.5)

      %

      Net revenues


      $

      4,224.2



      $

      3,925.0



      $

      299.2




      7.6

      %


















      Operating expenses:

















      Cost of sales(1)



      667.0




      604.0




      63.0




      10.4

      %

      Selling and marketing



      721.8




      713.5




      8.3




      1.2

      %

      General and administrative



      119.2




      111.3




      7.9




      7.1

      %

      Segment contribution


      $

      2,716.2



      $

      2,496.2



      $

      220.0




      8.8

      %

      Segment margin



      64.3

      %



      63.6

      %







      0.7

      %

      Segment gross margin(2)



      84.2

      %



      84.6

      %







      (0.4)

      %

      (1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Namenda XR® and Namenda® IR.


      (4) Includes Estrace® Cream sales of $34.3 million which were previously disclosed separately in the nine months ended September 30, 2018


      (5) Includes Minastrin® 24 sales of $6.6 million which were previously disclosed separately in the nine months ended September 30, 2018


      (6) Includes Lexapro® sales of $44.8 million which were previously disclosed separately in the nine months ended September 30, 2018


      (7) Includes PacPharma sales of $10.6 million which were previously disclosed separately in the nine months ended September 30, 2018





















       

      The following table details Allergan plc's product revenue for significant promoted products within the International segment for the three and nine months ended September 30, 2019 and 2018.


      Table 11


      ALLERGAN PLC


      International Product Revenue


      (Unaudited; in millions)





















      Three Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      312.9



      $

      289.0



      $

      23.9




      8.3

      %

      Lumigan®/Ganfort®



      89.7




      94.8




      (5.1)




      (5.4)

      %

      Alphagan®/Combigan®



      40.4




      40.5




      (0.1)




      (0.2)

      %

      Ozurdex®



      63.8




      25.8




      38.0




      147.3

      %

      Eye Drops(3)



      63.8




      66.8




      (3.0)




      (4.5)

      %

      Restasis®



      9.2




      13.6




      (4.4)




      (32.4)

      %

      Other Eye Care



      46.0




      47.5




      (1.5)




      (3.2)

      %

      Total Medical Aesthetics



      357.9




      369.0




      (11.1)




      (3.0)

      %

      Facial Aesthetics



      310.6




      303.6




      7.0




      2.3

      %

      Botox®Cosmetics



      165.6




      163.4




      2.2




      1.3

      %

      Juvederm®Collection



      144.7




      138.6




      6.1




      4.4

      %

      Belkyra®(Kybella®)



      0.3




      1.6




      (1.3)




      (81.3)

      %

      Plastic Surgery



      6.0




      35.9




      (29.9)




      (83.3)

      %

      Breast Implants



      5.7




      35.6




      (29.9)




      (84.0)

      %

      Other Plastic Surgery



      0.3




      0.3




      -




      0.0

      %

      Regenerative Medicine



      4.3




      3.3




      1.0




      30.3

      %

      Alloderm®



      2.1




      1.0




      1.1




      110.0

      %

      Other Regenerative Medicine



      2.2




      2.3




      (0.1)




      (4.3)

      %

      Body Contouring



      33.0




      22.5




      10.5




      46.7

      %

      Coolsculpting®Systems & Add On
      Applicators



      11.4




      8.3




      3.1




      37.3

      %

      Coolsculpting®Consumables



      21.6




      14.2




      7.4




      52.1

      %

      Skin Care



      4.0




      3.7




      0.3




      8.1

      %

      Botox® Therapeutics and Other



      146.5




      145.1




      1.4




      1.0

      %

      Botox®Therapeutics



      93.9




      92.9




      1.0




      1.1

      %

      Asacol®/Delzicol®



      7.2




      10.9




      (3.7)




      (33.9)

      %

      Constella®



      6.7




      5.7




      1.0




      17.5

      %

      Other Products



      38.7




      35.6




      3.1




      8.7

      %

      Other Revenues



      17.8




      18.5




      (0.7)




      (3.8)

      %

      Net revenues


      $

      835.1



      $

      821.6



      $

      13.5




      1.6

      %


















      Operating expenses:

















      Cost of sales(1)



      144.6




      130.7




      13.9




      10.6

      %

      Selling and marketing



      226.9




      206.0




      20.9




      10.1

      %

      General and administrative



      26.0




      35.1




      (9.1)




      (25.9)

      %

      Segment contribution


      $

      437.6



      $

      449.8



      $

      (12.2)




      (2.7)

      %

      Segment margin



      52.4

      %



      54.7

      %







      (2.3)

      %

      Segment gross margin(2)



      82.7

      %



      84.1

      %







      (1.4)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Optive® sales of $27.1 million which were previously disclosed separately in the three months ended September 30, 2018














































































































































































      Nine Months Ended September 30,



      Change




      2019



      2018



      Dollars



      %


      Total Eye Care


      $

      931.7



      $

      986.4



      $

      (54.7)




      (5.5)

      %

      Lumigan®/Ganfort®



      265.2




      295.7




      (30.5)




      (10.3)

      %

      Alphagan®/Combigan®



      118.9




      129.3




      (10.4)




      (8.0)

      %

      Ozurdex®



      207.9




      158.1




      49.8




      31.5

      %

      Eye Drops(3)



      176.5




      208.0




      (31.5)




      (15.1)

      %

      Restasis®



      31.5




      47.9




      (16.4)




      (34.2)

      %

      Other Eye Care



      131.7




      147.4




      (15.7)




      (10.7)

      %

      Total Medical Aesthetics



      1,067.9




      1,137.3




      (69.4)




      (6.1)

      %

      Facial Aesthetics



      966.5




      929.5




      37.0




      4.0

      %

      Botox®Cosmetics



      488.8




      483.4




      5.4




      1.1

      %

      Juvederm®Collection



      475.2




      440.8




      34.4




      7.8

      %

      Belkyra®(Kybella®)



      2.5




      5.3




      (2.8)




      (52.8)

      %

      Plastic Surgery



      (13.5)




      120.7




      (134.2)




      (111.2)

      %

      Breast Implants



      (14.5)




      119.6




      (134.1)




      (112.1)

      %

      Other Plastic Surgery



      1.0




      1.1




      (0.1)




      (9.1)

      %

      Regenerative Medicine



      11.2




      12.9




      (1.7)




      (13.2)

      %

      Alloderm®



      5.9




      5.5




      0.4




      7.3

      %

      Other Regenerative Medicine



      5.3




      7.4




      (2.1)




      (28.4)

      %

      Body Contouring



      93.3




      62.6




      30.7




      49.0

      %

      Coolsculpting®Systems & Add On
      Applicators



      33.6




      21.8




      11.8




      54.1

      %

      Coolsculpting®Consumables



      59.7




      40.8




      18.9




      46.3

      %

      Skin Care



      10.4




      11.6




      (1.2)




      (10.3)

      %

      Botox® Therapeutics and Other



      434.2




      461.4




      (27.2)




      (5.9)

      %

      Botox®Therapeutics



      286.6




      293.7




      (7.1)




      (2.4)

      %

      Asacol®/Delzicol®



      27.2




      35.0




      (7.8)




      (22.3)

      %

      Constella®



      17.0




      17.7




      (0.7)




      (4.0)

      %

      Other Products



      103.4




      115.0




      (11.6)




      (10.1)

      %

      Other Revenues



      50.5




      49.4




      1.1




      2.2

      %

      Net revenues


      $

      2,484.3



      $

      2,634.5



      $

      (150.2)




      (5.7)

      %


















      Operating expenses:

















      Cost of sales(1)



      399.9




      391.0




      8.9




      2.3

      %

      Selling and marketing



      718.1




      697.9




      20.2




      2.9

      %

      General and administrative



      80.1




      100.4




      (20.3)




      (20.2)

      %

      Segment contribution


      $

      1,286.2



      $

      1,445.2



      $

      (159.0)




      (11.0)

      %

      Segment margin



      51.8

      %



      54.9

      %







      (3.1)

      %

      Segment gross margin(2)



      83.9

      %



      85.2

      %







      (1.3)

      %

      (1)  Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.


      (2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.


      (3) Includes Optive® sales of $85.6 million which were previously disclosed separately in the nine months ended September 30, 2018







































       

      The following table provides a reconciliation of anticipated GAAP loss / income from continuing operations to non-GAAP performance net income attributable to shareholders for the twelve months ending December 31, 2019:



      Table 12



      Twelve months ending
      December 31, 2019

      (in millions, except per share information)


      LOW

      GAAP income/(loss) from continuing operations attributable to shareholders


      $

      (4,928.0)

      Adjusted for:




      Amortization



      5,870.0

      Acquisition, divestiture, licensing and other non-recurring charges



      166.0

      Accretion and fair-value adjustments to contingent consideration



      58.0

      Impairment/asset sales and related costs



      4,115.0

      Non-acquisition restructurings, including Global Supply Chain initiatives



      16.0

      Legal settlements



      765.0

      Income taxes on items above and other discrete income tax
      adjustments



      (567.0)

      Non-GAAP performance net income attributable to shareholders



      5,495.0





      Diluted earnings per share








      Diluted (loss) / income per share from continuing operations attributable to
      shareholders- GAAP


      $

      (14.98)





      Non-GAAP performance diluted net income per share attributable to
      shareholders


      $

      16.55





      Basic weighted average ordinary shares outstanding



      329.0

      Effect of dilutive securities:




      Dilutive shares



      3.0

      Diluted weighted average ordinary shares outstanding



      332.0

       

      SOURCE Allergan plc

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.